06 jun: Selskabsmeddelelse
07 jun: Indre værdi af SmallCap Danmark A/S er opgjort til 10,7 kr. pr. a..
06-06-2019 22:38:48

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement

Copenhagen, Denmark; June 6, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting

the board

decided to grant 6,464 restricted stock units and 21,343 warrants to employees of the company and three of the company's subsidiaries.

Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 1,147.50.

The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the board of directors in accordance with the general guidelines for incentive-based remuneration adopted by the shareholders at the annual general meeting. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Stock information > Restricted stock units.

The exercise price for each warrant is DKK 1,147.50. Each warrant is awarded cost-free and entitles the owner to subscribe one share of nominally DKK 1 subject to payment of the exercise price. By application of the Black-Scholes formula, the fair value of each warrant can be calculated as DKK 347.62.

The warrants vest three years after the grant date, and all warrants expire at the seventh anniversary of the grant date. The new warrants have been granted on the terms and conditions set out in the warrant program adopted by the board of directors on March 28, 2017. Information concerning Genmab’s warrant schemes can be found on www.genmab.com under Investors > Stock information > Warrants.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies and the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products.  Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact:          

Marisol Peron, Corporate Vice President, Communications & Investor Relations

T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:

Andrew Carlsen, Senior Director, Investor Relations

T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

Company Announcement no. 24

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

logo.jpg

Relateret indhold
19 jun - 
Genmab: Blackrock er tilbage i storaktionærklubben
12 jun - 
Genmab/Jyske: Forsinket godkendelse har øget risiko for..
11 jun - 
Tirsdagens aktier: Ambu og Novo toppede marked klædt i ..
Relateret debat
25 jun - 
Ja det begynder med M... .
25 jun - 
der sker jo hele tiden noget - er det noget specielt du..
25 jun - 
Så er Black Rock lige under de 5 % igen (4,97%). Bare r..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
19 jun
GEN
Black Rock ligger lige nu med Ca 5% af alle Genmab aktier, de ligger og svinger på lige over og unde..
3
19 jun
GEN
God signalværdi
2
19 jun
GEN
Interessant 👍
1
19 jun
GEN
Nu over igen... Lad os håbe de har appetit på mange flere... Og at nogle shorts snart skal indløses...
1

Vestas indgår forlig med GE i patentsag: Betaler fortroligt beløb

25-06-2019 16:36:29
Vestas har indgået forlig med den amerikanske rival Generel Electric i forbindelse med flere patentsager. Det betyder, at sagerne nu droppes, oplyser de to selskaber i en meddelelse.Vestas betaler i forbindelse med forliget en fortrolig sum penge til GE. Derudover giver forliget en krydslicens til paterne, der omhandler teknologi, der bruges til at sikre stabiliteten i vindmøllerne under forstyrre..

Amerikanske medicinalvirksomheder slår sig sammen i millardhandel

Relaterede nyheder
25-06-2019 13:05:35
Den amerikanske medicinalvirksomhed Abbvie overtager sin kollega Allergan i en handel til en værdi af 63 mia. dollar.Det bekræfter de to selskaber, efter at Wall Street Journal tidligere tirsdag kunne citere kilder for, at opkøbet var på vej.Ifølge aftalen betaler Abbvie 188,24 dollar per aktie i Allergan, svarende til en præmie på 45 pct. sammenlignet med lukkekursen på Allergan mandag.Aktien i A..

Mærsk lancerer nyt onlineprodukt: Vil bryde med overbookinger

25-06-2019 10:36:22
(Korr: ændring i andet afsnit. Ordet "betales" er ændret til "aftales".)A.P. Møller-Mærsk lancerer et nyt onlineprodukt, der skal være med til at gøre transporten af containere mere simpel for kunderne, og som samtidig kan være med til at undgå overbookinger.Produktet går under navnet Maersk Spot, og det sikrer kunderne en garanti for, at fragten bliver lastet, skriver Mærsk i en pressemeddelelse ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Britisk investeringsfirma reducerer shortposition i to danske aktier
2
Danske Bank/Nordea: Sænker kursmål med 10 kr.
3
Detektivfirma: Danske Bank fyrede os af frygt for hvidvasksag
4
Aktier/tendens: Inspirationen hælder mest til den negative side
5
Ørsted lægger to enheder sammen: Koncerndirektør forlader selskabet

Relaterede aktiekurser

Genmab A/S 1.188,50 -1,0% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
26. juni 2019 04:32:50
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190527.1 - EUROWEB3 - 2019-06-26 04:32:50 - 2019-06-26 04:32:50 - 1 - Website: OKAY